Grant List
Represents Grant table in the DB
GET /v1/grants?sort=awardee_organization
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=awardee_organization", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=awardee_organization", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=awardee_organization", "prev": null }, "data": [ { "type": "Grant", "id": "10497", "attributes": { "award_id": "75N93022C00050-0-9999-1", "title": "CAPTURING MEDICAL MISINFORMATION IN SOCIAL MEDIA USING AN ADVANCED AI SOLUTION SET", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-08-08", "end_date": "2023-08-07", "award_amount": 300000, "principal_investigator": { "id": 26504, "first_name": "MANOOCHEHR", "last_name": "GHIASSI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "To develop digital tools to identify and combat malicious digital bots that spread misinformation about infectious disease treatments and vaccines, including COVID-19 vaccines.", "keywords": [ "2019-nCoV", "Basic Science", "COVID-19 vaccine", "Coronavirus", "Medical", "Misinformation", "Vaccines", "combat", "digital", "infectious disease treatment", "social media", "tool" ], "approved": true } }, { "type": "Grant", "id": "15499", "attributes": { "award_id": "75N95024C00025-0-9999-1", "title": "NCATS CYBERSECURITY SERVICES PROGRAM SUPPORT. POP: 07/29/2024 - 09/18/2024.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2024-07-29", "end_date": "2024-09-18", "award_amount": 297510, "principal_investigator": { "id": 32046, "first_name": "MARK", "last_name": "BACKUS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C program is essentially a medium sized business, consisting of thousands of researchers, requiring enterprise level information technology (IT) support as part of a virtual research organization (VRO). This contract is necessary to ensure that NCATS and N3C can continue to provide adequate support for a secure, collaborative, VRO. This contract allows for continued support of the VRO which supports all of the required information technology functions to support an environment of over 4,000 users, including cloud-based productivity tools, a service desk, commercial and open-source deployments of analytical tools for the community to use, and expansion of the data types available for analysis, such as imaging, viral variant genomic sequences, etc. The common need is to share a collaborative cloud environment capable of ingesting billions of data points and performing a variety of complex analyses against multimodal data types, ranging from pathology and radiology data, synthetic data, genomic information, electronic health records (EHRs) and a wide variety of others. All of this must be done while meeting the highest levels of security and privacy, given the sensitivity of some of the data types being collected and the importance of the work being done in the environment. This contract provides IT security support for all of these enterprise IT efforts.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8432", "attributes": { "award_id": "75N92021C00018-0-9999-1", "title": "RADX TECH 2375 - POINT OF NEED, SALIVA-BASED, COVID-19 TESTING PLATFORMS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-07-01", "end_date": "2022-06-30", "award_amount": 3700000, "principal_investigator": { "id": 22342, "first_name": "DAVE", "last_name": "BEEBE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The key conceptual insight underpinning this proposal is that detecting individuals who are most likely to transmit SARS-CoV-2 is essential to mitigating the pandemic and reopening America. Our approach consciously contrasts with most existing nucleic acid testing platforms, which begin from the premise that maximizing detection sensitivity is the goal. We argue that striving for maximum sensitivity is at odds with the current needs for broad population based testing and that in a public health emergency, nucleic acid testing should be designed to maximize the number of people who can be tested for high viral loads consistent with shedding of live virus, in the greatest number of settings, at the lowest possible cost. To achieve this we couple a proven, ultrafast nucleic acid extraction method with rapid detection of amplified nucleic acids in an assay that can be both massively scaled in centralized reference labs and also used by point-of-care testing providers. The key enabling technology is a new, but proven, nucleic acid extraction method that reliably, quickly, and easily extracts, purifies, and concentrates viral RNA from a variety of sample types including nasal swabs and saliva in a highly parallel format. RNA prepared using this extraction method can be reliably amplified and detected using a simple colorimetric assay following isothermal amplification. These two technologies combined provide a testing platform that can enable millions of tests a week, at low cost, in both centralized laboratories and at point-of-care using technicians with no specialized training to support test/isolate/trace.", "keywords": [ "Americas", "Biological Assay", "COVID-19 testing", "Conscious", "Goals", "Individual", "Laboratories", "Methods", "Nucleic Acid Amplification Tests", "Nucleic Acids", "Provider", "RADx Tech", "RNA", "SARS-CoV-2 transmission", "Saliva", "Sampling", "Technology", "Testing", "Training", "Viral Load result", "Virus", "amplification detection", "base", "cost", "design", "detection sensitivity", "insight", "isothermal amplification", "nasal swab", "pandemic disease", "point of care", "point of care testing", "population based", "public health emergency", "rapid detection", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "10554", "attributes": { "award_id": "75N94021C00007-P00005-9999-1", "title": "DEVELOPMENT OF AN ELECTRONIC CARE PLAN FOR PERSONS WITH MULTIPLE CHRONIC CONDITIONS (E-CARE)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2023-09-29", "award_amount": 111971, "principal_investigator": { "id": 26567, "first_name": "EVELYN", "last_name": "GALLEGO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Through funding made available from the Department of Health and Human Services’ Patient-Centered Outcomes Research Trust Fund (PCOR TF), the NIDDK has partnered with the Agency for Healthcare Research and Quality (AHRQ) on the development and testing of a pilot suite of interoperable electronic (e-) care planning tools to facilitate aggregation and sharing of critical patient-centered data across home-, community-, clinic- and research-based settings for persons with multiple chronic conditions (MCC), including chronic kidney disease (CKD), type 2 diabetes mellitus (T2D), cardiovascular disease (CVD), chronic pain, and post-acute sequelae of SARS-CoV-2 infection (PASC). Care plans are a prominent part of multifaceted, care coordination interventions that reduce mortality and hospitalizations and improve disease management and satisfaction. In addition, proactive care planning promotes person-centeredness, improves outcomes, and reduces the cost of care. Development of care plans based on standardized data—leveraging standards such as Fast Healthcare Interoperability Resources (FHIR) and Substitutable Medical Apps, Reusable Technology (SMART) (https://smarthealthit.org/) on FHIR—has been proposed as a method for enabling electronic systems to pull together and share data elements automatically and dynamically. Such aggregated data would not only provide actionable information to identify and achieve health and wellness goals for individuals with MCC, but also would reduce missingness and improve quality of point-of-care data for use in pragmatic research. The NIDDK is leading the development component of the project, while real-world testing is being led by AHRQ.", "keywords": [ "Cardiovascular Diseases", "Caregivers", "Caring", "Chronic", "Chronic Kidney Failure", "Coordination and Collaboration", "Data", "Data Aggregation", "Data Element", "Development", "Disease Management", "Fast Healthcare Interoperability Resources", "Funding", "Goals", "Health", "Health Status", "Home", "Hospitalization", "Individual", "Intervention", "Medical", "Methods", "National Institute of Diabetes and Digestive and Kidney Diseases", "Non-Insulin-Dependent Diabetes Mellitus", "Outcomes Research", "Patient-Focused Outcomes", "Patients", "Persons", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Research", "System", "Technology", "Testing", "Trust", "United States Agency for Healthcare Research and Quality", "United States Dept. of Health and Human Services", "base", "care coordination", "care costs", "chronic pain", "community clinic", "data management", "data sharing", "data standards", "improved", "improved outcome", "interoperability", "mortality", "multiple chronic conditions", "patient oriented", "point of care", "satisfaction", "tool" ], "approved": true } }, { "type": "Grant", "id": "13498", "attributes": { "award_id": "75N95020D00011-0-759502300002-1", "title": "NCATS CYBERSECURITY SERVICES DIVISION PROGRAM SUPPORT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-09-29", "end_date": "2024-02-28", "award_amount": 1427260, "principal_investigator": { "id": 29624, "first_name": "", "last_name": "", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, https://covid.cd2h.org/, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C program is essentially a medium sized business, consisting of thousands of researchers, requiring enterprise level information technology (IT) support as part of a virtual research organization (VRO). This contract is necessary to ensure that NCATS and N3C can continue to provide adequate support for a secure, collaborative, VRO. This contract allows for continued support of the VRO which supports all of the required information technology functions to support an environment of over 4,000 users, including cloud-based productivity tools, a service desk, commercial and open-source deployments of analytical tools for the community to use, and expansion of the data types available for analysis, such as imaging, viral variant genomic sequences, etc. The common need is to share a collaborative cloud environment capable of ingesting billions of data points and performing a variety of complex analyses against multimodal data types, ranging from pathology and radiology data, synthetic data, genomic information, electronic health records (EHRs) and a wide variety of others. All of this must be done while meeting the highest levels of security and privacy, given the sensitivity of some of the data types being collected and the importance of the work being done in the environment. This contract provides IT security support for all of these enterprise IT efforts.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8070", "attributes": { "award_id": "75N92021P00061-0-0-1", "title": "EXERCISE OPTION PERIOD 2 TO PROVIDE SERVICES IN SUPPORT OF NIBIB COVID-19 RADX PROJECT FOR THE PERIOD 10/16/2021 - 01/31/2022", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-02-01", "end_date": "2021-05-31", "award_amount": 14871886, "principal_investigator": { "id": 23963, "first_name": "ELIAS", "last_name": "CARO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has an open solicitation for proposals to provide up to $500 million across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.", "keywords": [ "American", "COVID-19", "COVID-19 detection", "COVID-19 diagnostic", "COVID-19 testing", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Contracts", "Department of Defense", "Development", "Device Designs", "Diagnostic tests", "Ensure", "Exercise", "Exhalation", "Funding", "Goals", "Home", "Improve Access", "Laboratories", "Life Cycle Stages", "Modification", "National Institute of Biomedical Imaging and Bioengineering", "Patients", "Performance", "Point of Care Technology", "Privatization", "Program Development", "RADx", "Readiness", "Research", "Saliva", "Sampling", "Seasons", "Sensitivity and Specificity", "Services", "Speed", "Structure", "Technology", "Test Result", "Testing", "Time", "TimeLine", "United States National Institutes of Health", "Validation", "Virus", "base", "commercialization", "cost", "design", "detection limit", "flu", "handheld mobile device", "home test", "improved", "innovation", "meetings", "novel", "point of care", "product development", "programs", "scale up", "technology development", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "9455", "attributes": { "award_id": "75N92019P00328-P00007-0-1", "title": "THE PURPOSE OF THIS MODIFICATION IS TO EXTEND LINE ITEM 1005 TO 1/31/21 FOR CONTINUING ENTREPRENEURIAL SERVICES FOR THE COVID-19 PANDEMIC.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2019-08-16", "end_date": "2021-08-15", "award_amount": 3000026, "principal_investigator": { "id": 23963, "first_name": "ELIAS", "last_name": "CARO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has an open solicitation for proposals to provide up to $500 million across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.", "keywords": [ "American", "COVID-19", "COVID-19 detection", "COVID-19 diagnostic", "COVID-19 pandemic", "COVID-19 testing", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Contracts", "Department of Defense", "Development", "Device Designs", "Diagnostic tests", "Ensure", "Exhalation", "Funding", "Goals", "Home", "Improve Access", "Laboratories", "Life Cycle Stages", "Modification", "National Institute of Biomedical Imaging and Bioengineering", "Patients", "Performance", "Point of Care Technology", "Privatization", "Program Development", "RADx", "Readiness", "Research", "Saliva", "Sampling", "Seasons", "Sensitivity and Specificity", "Services", "Speed", "Structure", "Technology", "Test Result", "Testing", "Time", "TimeLine", "United States National Institutes of Health", "Validation", "Virus", "base", "commercialization", "cost", "design", "detection limit", "flu", "handheld mobile device", "home test", "improved", "innovation", "meetings", "novel", "point of care", "product development", "programs", "scale up", "technology development", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "9142", "attributes": { "award_id": "75N93020C00022-0-9999-1", "title": "DEVELOPMENT OF FERRET REAGENTS FOR USE IN THE CHARACTERIZATION OF IMMUNE RESPONSES TO RESPIRATORY INFECTIONS IN THE FERRET MODEL.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-01", "end_date": "2022-06-30", "award_amount": 572817, "principal_investigator": { "id": 24917, "first_name": "TORI", "last_name": "RACE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Ferrets represent excellent models of human respiratory viruses such as influenza A virus, SARS-CoV and MERS-CoV. The goal of this proposal is to generate antibodies for analyzing immune cells and cytokine responses during respiratory infections in ferrets. The main focuses are immune cell markers and cytokines produced by these cells during immune responses. The contractor plans to use standard hybridoma techniques to generated monoclonal antibodies will then undergo extensive immunological characterization using various methods to show the specificity to recombinant immunogens as well as selected ferret samples.", "keywords": [ "Antibodies", "Antigens", "Cells", "Contractor", "Ferrets", "Generations", "Goals", "Hybridomas", "Immune", "Immune response", "Immunization", "Immunologics", "Influenza A virus", "Methods", "Middle East Respiratory Syndrome Coronavirus", "Modeling", "Monoclonal Antibodies", "Mus", "Proteins", "Reagent", "Recombinants", "Respiratory Tract Infections", "SARS coronavirus", "Sampling", "Specificity", "Techniques", "Validation", "cytokine", "human model", "respiratory virus", "response" ], "approved": true } }, { "type": "Grant", "id": "8222", "attributes": { "award_id": "75N92021C00008-0-9999-1", "title": "AWARD A CONTRACT FOR RADX TECH - QORVO TO SECURE AN EUA APPROVED POC ANTIGEN TEST SYSTEM AS WELL AS INCREASE AN INCREMENTAL DAILY CARTRIDGE PRODUCTION", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-02", "end_date": "2022-04-01", "award_amount": 24361759, "principal_investigator": { "id": 24054, "first_name": "HANJOON", "last_name": "RYU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "Qorvo Biotechnologies’ (Qorvo) investigational Bulk Acoustic Wave (BAW) sensor detection platform (Omnia TM ) targets viral antigen testing for use in Point-of-Care (POC) settings. The platform is designed to produce reliable and quantitative results matching central lab performance and improving confidence in POC tests. Developed over a 6+ year timeframe, the technological differentiation is in the detection core, where Qorvo has optimized the BAW device that is made at low cost and high volume (millions per day for cell phones) for liquid biosensing. Detection of SARS-CoV-2 antigen occurs with a shift in the biosensor resonance frequency as antigen (Nucleocapsid and Spike S1) protein mass accumulates at specific probes on the sensor surface. Traditional optical/ fluorescence sensing is replaced by high-sensitivity, high-specificity solid-state mass-based sensing. While this proposal is focused on antigen test development, Qorvo has submitted for a SARS-CoV-2 IgG antibody test EUA on the same BAW platform that was completed in less than 10 weeks with world-class performance of 100% specificity and 100% negative cross reactivity. Given this is just one of over a dozen other assays previously run through this platform, the results give us extreme confidence in our ability to execute the viral antigen technical and timeline tasks. Qorvo has invested heavily in manufacturing infrastructure commercial development for the antibody test as well as existing veterinary and human development products so the antigen will be part of a product suite. RADx assistance will enable acceleration of regulatory and US-based high-volume manufacturing ramp.", "keywords": [ "2019-nCoV", "Acceleration", "Acoustics", "Antigens", "Biological Assay", "Biosensing Techniques", "Biosensor", "Cellular Phone", "Contracts", "Detection", "Development", "Devices", "Fluorescence", "Frequencies", "Human Development", "Immunoglobulin G", "Infrastructure", "Investigation", "Liquid substance", "Nucleocapsid", "Optics", "Performance", "Production", "Proteins", "RADx", "RADx Tech", "Ramp", "Running", "SARS-CoV-2 antigen", "Secure", "Specificity", "Surface", "System", "TimeLine", "Viral Antigens", "antibody test", "antigen test", "base", "cost", "cross reactivity", "design", "detection platform", "improved", "point of care", "point of care testing", "product development", "sensor", "solid state" ], "approved": true } }, { "type": "Grant", "id": "10379", "attributes": { "award_id": "75N93022C00044-0-9999-1", "title": "SBIR TOPIC 107 REAGENTS FOR IMMUNOLOGIC ANALYSIS OF NON- MAMMALIAN AND UNDERREPRESENTED MAMMALIAN MODELS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2024-09-29", "award_amount": 596519, "principal_investigator": { "id": 24917, "first_name": "TORI", "last_name": "RACE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The hamster is a well-established model for several infectious diseases including influenza and SARS-CoV-2. Lack of hamster reagents has hampered pre-clinical studies of viral pathogenesis, host immunity, and vaccine development. The objectives of this proposal are to produce and test monoclonal antibodies against 10 cytokines and chemokines and 4 T cell surface markers for characterizing cytokine responses and examining T cells activation in the hamster models of respiratory infections. Completion of this project will provide high-affinity monoclonal antibodies that allow investigators to distinguish innate and adaptive inflammatory cytokine and chemokine responses as well as activated T cells, memory T cells, tissue resident memory T cells, and regulatory T cells in the hamster models of infectious diseases.", "keywords": [ "2019-nCoV", "Affinity", "Cell surface", "Cells", "Communicable Diseases", "Generations", "Hamsters", "Immunity", "Immunization", "Immunologics", "Inflammatory", "Influenza", "Memory", "Modeling", "Monoclonal Antibodies", "Mus", "Proteins", "Reagent", "Recombinant Proteins", "Recombinants", "Regulatory T-Lymphocyte", "Research Personnel", "Respiratory Tract Infections", "Serum", "Small Business Innovation Research Grant", "T memory cell", "T-Cell Activation", "T-Lymphocyte", "Testing", "Tissue Sample", "Tissues", "Validation", "Viral Pathogenesis", "chemokine", "cytokine", "infectious disease model", "preclinical study", "response", "vaccine development" ], "approved": true } } ], "meta": { "pagination": { "page": 1, "pages": 1424, "count": 14236 } } }